medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2025-23-103-107medalphabet-4669Research ArticleСтатьиВлияние комбинированной терапии CO2 лазером и транексамовой кислотой на качество жизни пациентов с мелазмой: сравнительное исследование с использованием шкалы melasqolThe influence of combined CO2 laser therapy and tranexamic acid on the quality of life of patients with melasma: a comparative study using the mekasqol scalehttps://orcid.org/0009-0004-0930-1229ЛогачеваН. С.LogachevaN. S.

Логачева Наталья Сергеевна, соискатель ученой степени кандидата наук кафедры дерматовенерологии и косметологии

Москва

Logacheva Natalia S., candidate for the academic degree of candidate of sciences at Dept of Dermatovenereology and Cosmetology

Moscow

 

dr.logacheva@gmail.comhttps://orcid.org/0000-0001-8719-8619ШароваА. А.SharovaA. A.

Шарова Алиса Александровна, д.м.н., профессор кафедры дерматовенерологии и косметологии; доцент кафедры реконструктивной и пластической хирургии, косметологии и клеточных технологий; научный руководитель

Москва 

Sharova Alisa A., DM Sci (habil.), professor at Dept of Dermatovenereology andCosmetology; associate professor at Dept of Reconstructive and Plastic Surgery,Cosmetology, and Cellular Technologies; scientific supervisor 

Moscow

aleca@mail.ruhttps://orcid.org/0000-0002-0238-6563ШатохинаЕ. А.ShatokhinaE. A.

Шатохина Евгения Афанасьевна, д.м.н., профессор кафедры дерматовенерологии и косметологии; ведущий научный сотрудник отдела внутренних болезней 

Москва

Shatokhina Evgeniya A., DM Sci (habil.), professor at Dept of Dermatovenereology and Cosmetology; leading researcher at Dept of Internal Medicine

 Moscow 

e.a.shatokhina@gmail.comФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской ФедерацииРоссияCentral State Medical Academy of the Administrative Department of the President of the Russian Federation;Russian FederationФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской Федерации; ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России (Пироговский университет); ООО «Клиника эстетической медицины „Чистые пруды“»РоссияCentral State Medical Academy of the Administrative Department of the President of the Russian Federation; N.I. Pirogov Russian National Research Medical University (Pirogov University); Aesthetic medical clinic “Chistiye prudy”Russian FederationФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской Федерации; ФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова» обособленное подразделение Медицинский научно-образовательный институт МГУ (Университетская клиника МГУ)РоссияCentral State Medical Academy of the Administrative Department of the President of the Russian Federation; Medical Scientific and Educational Center of Lomonosov Moscow State UniversityRussian Federation202511112025123Дерматология (2)103107Copyright © Логачева Н.С., Шарова А.А., Шатохина Е.А., 20252025Логачева Н.С., Шарова А.А., Шатохина Е.А.Logacheva N.S., Sharova A.A., Shatokhina E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4669

Мелазма – хроническое приобретенное заболевание кожи (меланодермия), которое проявляется образованием пигментных пятен на лице, преимущественно в области лба, щек и верхней губы. Это состояние способно оказывать значительное негативное влияние на психосоциальное благополучие и качество жизни пациентов. Поэтому требуются эффективные методы лечения и оценка их влияния на качество жизни.Цель исследования. Сравнить эффективность и безопасность комбинированной терапиии СО2‑лазером и местным раствором транексамовой кислоты с монотерапией СО2‑лазером в улучшении качества жизни пациентов с мелазмой, оцениваемого с помощью специфической шкалы MELASQoL.Материалы и методы. В исследовании участвовали 40 пациентов с клиническими проявлениями мелазмы в области лица. Половине испытуемых (основная группа) проводили 3 комбинированные процедуры фракционного фототермолиза с помощью СО2‑лазера (10600 нм) с последующим нанесением 5% раствора транексамовой кислоты с интервалом 4 недели. Другая половина (контрольная группа) получала монотерапию только на СО2‑лазере с той же периодичностью. Для оценки терапевтической динамики использовались два индекса: индекс площади и тяжести мелазмы MASI (Melasma Area and Severity Index) и индекс оценки качества жизни пациентов с мелазмой MELASQоL (The Melasma Quality of Life scale).Выводы. Комбинированная терапия фракционным СО2‑лазером и транексамовой кислотой превосходит монотерапию лазером в улучшении качества жизни пациентов с мелазмой, что подтверждается значимым снижением баллов по шкале MELASQoL. Оценка качества жизни с помощью MELASQoL является важным инструментом для комплексной оценки эффективности лечения мелазмы.

Melasma is a chronic acquired skin condition (melanodermia) characterized by the formation of pigmented spots on the face, predominantly in the forehead, cheeks, and upper lip areas. This condition can have a significant negative impact on the psychosocial well‑being and quality of life of patients. Therefore, effective treatment methods and an evaluation of their impact on quality of life are necessary.Objective of the study. To compare the effectiveness and safety of combined CO2‑laser therapy and topical tranexamic acid solution with CO2-laser monotherapy in improving the quality of life of patients with melasma, assessed using the MELASQoL scale.Materials and methods. The study included 40 patients with clinical manifestations of melasma on the face. Half of the participants (main group) underwent 3 combined fractional photothermolysis procedures using a CO2‑laser (10600 nm), followed by the application of a 5% tranexamic acid solution with a 4‑week interval. The other half (control group) received monotherapy with only the CO2‑laser at the same intervals. Two indices were used to assess therapeutic dynamics: the Melasma Area and Severity Index (MASI) and the Melasma Quality of Life scale (MELASQoL).Conclusions. Combined therapy with fractional CO2‑laser and tranexamic acid is superior to laser monotherapy in improving the quality of life of patients with melasma, as confirmed by a significant reduction in MELASQoL scores. The assessment of quality of life using MELASQoL is an important tool for the comprehensive evaluation of melasma treatment effectiveness.

мелазмагиперпигментациятранексамовая кислотаСО2‑лазерфракционная шлифовкалазер‑ассоциированное введениеmelasmahyperpigmentationtranexamic acidСО2‑laserfractional resurfacinglaser‑assisted drug deliveryReferencesОбщероссийская общественная организация «Российское общество дерматовенерологов и косметологов»: хлоазма, 2022 г.All-Russian public organization «Russian Society of Dermatovenerologists and Cosmetologists»: chloasma, 2022. (In Russ.).Стенько А.Г., Иконникова Е.В., Круглова Л.С. Современный терапевтический подход к коррекции гиперпигментации. Пластическая хирургия и эстетическая медицина, 2020 г.Stenko A.G., Ikonnikova E.V., Kruglova L.S. Modern therapeutic approach to hyperpigmentation correction. Plastic surgery and aesthetic medicine, 2020. (In Russ.).Эрнандес Е.И., Пигментация в практике косметолога, Косметика и медицина, 2020 г.Hernandez E.I., Pigmentation in the practice of a cosmetologist, Cosmetics and Medicine, 2020. (In Russ.).Zhu J.W. et al. Tranexamic Acid Inhibits Angiogenesis and Melanogenesis in Vitro by Targeting VEGF Receptors. Int J Med Sci 2020.Zhu J.W. et al. Tranexamic Acid Inhibits Angiogenesis and Melanogenesis in Vitro by Targeting VEGF Receptors. Int J Med Sci 2020.Konisky H, Balazic E, Jaller JA, et al. Tranexamic acid in melasma: A focused review on drug administration routes. J Cosmet Dermatol. 2023 Apr; 22 (4): 1197–1206.Konisky H, Balazic E, Jaller JA, et al. Tranexamic acid in melasma: A focused review on drug administration routes. J Cosmet Dermatol. 2023 Apr; 22 (4): 1197–1206.Tse T.W., Hui E. Tranexamic acid: an important adjuvant in the treatment of melаsma. J. Cosmet. Dermatol. 2013; 12: 57–66.Tse T.W., Hui E. Tranexamic acid: an important adjuvant in the treatment of melаsma. J. Cosmet. Dermatol. 2013; 12: 57–66.Xing X., Xu Z., Chen L., et al. Tranexamic acid inhibits melanogenesis partially via stimulation of TGF β1 expression in human epidermal keratinocytes. Exp Dermatol 2022; 31 (4): 633–640.Xing X., Xu Z., Chen L., et al. Tranexamic acid inhibits melanogenesis partially via stimulation of TGF β1 expression in human epidermal keratinocytes. Exp Dermatol 2022; 31 (4): 633–640.Feng J, Shen S, Song X. et al. Efficacy and safety of laser assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and metaanalysis. J Cosmet Laser Ther. 2022 Nov 17; 24 (6–8): 73–79.Feng J, Shen S, Song X. et al. Efficacy and safety of laser assisted delivery of tranexamic acid for the treatment of melasma: a systematic review and metaanalysis. J Cosmet Laser Ther. 2022 Nov 17; 24 (6–8): 73–79.Khan QA, Abdi P, Farkouh C et al. Effectiveness of laser and topical tranexamic acid combination therapy in melasma: An updated systematic review and meta analysis of randomized controlled trials. Lasers Med Sci. 2023 Jun 16; 38 (1).Khan QA, Abdi P, Farkouh C et al. Effectiveness of laser and topical tranexamic acid combination therapy in melasma: An updated systematic review and meta analysis of randomized controlled trials. Lasers Med Sci. 2023 Jun 16; 38 (1).Jow T, Hantash BM. Hydroquinone induced depigmentation: case report and review of the literature. Dermatitis. 2014 Jan Feb; 25 (1): e1–5.Jow T, Hantash BM. Hydroquinone induced depigmentation: case report and review of the literature. Dermatitis. 2014 Jan Feb; 25 (1): e1–5.Shivaram K, Edwards K, Mohammad TF. An update on the safety of hydroquinone. Arch Dermatol Res. 2024 Jun 8; 316 (7): 378.Shivaram K, Edwards K, Mohammad TF. An update on the safety of hydroquinone. Arch Dermatol Res. 2024 Jun 8; 316 (7): 378.Ribeiro Gonçalves O, de Souza MCF, Rocha AV, et al. Assessing the efficacy of oral Tranexamic Acid as adjuvant of Topic Triple Combination Cream Therapy in Melasma: A Meta Analysis of Randomized Controlled Trials. Clin Exp Dermatol. 2024 Jun 8: llae 226.Ribeiro Gonçalves O, de Souza MCF, Rocha AV, et al. Assessing the efficacy of oral Tranexamic Acid as adjuvant of Topic Triple Combination Cream Therapy in Melasma: A Meta Analysis of Randomized Controlled Trials. Clin Exp Dermatol. 2024 Jun 8: llae 226.Hiramoto K, Yamate Y, Sugiyama D et al. Tranexamic acid inhibits the plasma and non irradiated skin markers of photoaging induced by long term UVA eye irradiation in female mice. Biomed Pharmacother. 2018 Nov; 107: 54–58.Hiramoto K, Yamate Y, Sugiyama D et al. Tranexamic acid inhibits the plasma and non irradiated skin markers of photoaging induced by long term UVA eye irradiation in female mice. Biomed Pharmacother. 2018 Nov; 107: 54–58.Sklar L. R. et al. Laser assisted drug delivery: a review of an evolving technology. Lasers Surg. 2014Sklar L. R. et al. Laser assisted drug delivery: a review of an evolving technology. Lasers Surg. 2014Searle T, Ali FR, Al Niaimi F. Lessons Learned from the First Decade of Laser Assisted Drug Delivery. Dermatol Ther (Heidelb). 2021 Feb;11(1):93–104.Searle T, Ali FR, Al Niaimi F. Lessons Learned from the First Decade of Laser Assisted Drug Delivery. Dermatol Ther (Heidelb). 2021 Feb;11(1):93–104.Tawfic SO, Abdel Halim DM, Albarbary A et al. Assessment of combined fractional CO2 and tranexamic acid in melasma treatment. Lasers Surg Med. 2019 Jan; 51 (1): 27–33.Tawfic SO, Abdel Halim DM, Albarbary A et al. Assessment of combined fractional CO2 and tranexamic acid in melasma treatment. Lasers Surg Med. 2019 Jan; 51 (1): 27–33.Tawfic SO, Abdel Hay RM, Abouelazm DI et al. Tranexamic Acid Microinjection Alone Versus Its Combination With Fractional Carbon Dioxide Laser in Melasma Treatment: A Dermoscopic Evaluation. Dermatol Surg. 2022 May 1; 48 (5): 556–561.Tawfic SO, Abdel Hay RM, Abouelazm DI et al. Tranexamic Acid Microinjection Alone Versus Its Combination With Fractional Carbon Dioxide Laser in Melasma Treatment: A Dermoscopic Evaluation. Dermatol Surg. 2022 May 1; 48 (5): 556–561.Haedersdal M. et al. Fractional CO2 laser assisted drug delivery. Lasers Surg Med. 2010Haedersdal M. et al. Fractional CO2 laser assisted drug delivery. Lasers Surg Med. 2010Bloom B.S., Brauer J.A., Geronemus R.G. Ablative fractional resurfacing in topical drug delivery: an update and outlook. Dermatol. Surg. 2013; 39: 839–848.Bloom B.S., Brauer J.A., Geronemus R.G. Ablative fractional resurfacing in topical drug delivery: an update and outlook. Dermatol. Surg. 2013; 39: 839–848.Brauer J.A., Krakowski A.C., Bloom B.S. et al. Convergence of anatomy, technology, and therapeutics: a review of laser assisted drug delivers. Semin. Cutan. Med. Surg. 2014; 33:176–181.Brauer J.A., Krakowski A.C., Bloom B.S. et al. Convergence of anatomy, technology, and therapeutics: a review of laser assisted drug delivers. Semin. Cutan. Med. Surg. 2014; 33:176–181.Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health related quality of life instrument for women with melasma. The British journal of dermatology. 2003; 149 (3): 572–7.Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health related quality of life instrument for women with melasma. The British journal of dermatology. 2003; 149 (3): 572–7.Harumi O, Goh CL. The effect of melasma on the quality of life in a sample of women living in singapore. The Journal of clinical and aesthetic dermatology. 2016; 9 (1): 21–4.Harumi O, Goh CL. The effect of melasma on the quality of life in a sample of women living in singapore. The Journal of clinical and aesthetic dermatology. 2016; 9 (1): 21–4.Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on quality of life in a sample of women living in southern Brazil. Journal of the European Academy of Dermatology and Venereology: JEADV. 2008; 22 (6): 655–62.Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on quality of life in a sample of women living in southern Brazil. Journal of the European Academy of Dermatology and Venereology: JEADV. 2008; 22 (6): 655–62.

The authors declare that there are no conflicts of interest present.